Pharmaceuticals

With a strong cash position and key clinical trials advancing for ALS and FTD, Coya is executing a disciplined strategy to tackle neurodegenerative diseases.

The consumer health giant is buying back $2B in bonds to refinance its debt. It's a bold play on interest rates and a declaration of its financial independence.

With the appointment of Dr. Jeffrey Sherman, Kalohexis signals a major push to conquer the challenging metabolic disease market with its novel pipeline.

The biotech has gone all-in on its lead drug, bel-sar, cutting 20% of staff and shelving a promising bladder cancer program to secure its financial future.

With a massive Series B and the launch of a Phase 3 study, Vaderis Therapeutics is poised to deliver the first-ever approved therapy for a long-neglected rare disease.

As Johnson & Johnson prepares for a key investor conference, its strategy hinges on a potent mix of new drugs, robotic surgery, and a leaner focus.

With promising early data and a robust balance sheet, Palisade Bio is advancing its targeted IBD therapy, PALI-2108, into crucial Phase 2 trials.

New 48-week data for envudeucitinib shows 54% of patients achieved complete skin clearance, setting a new bar for oral therapies and positioning Alumis for market disruption.

Strong Attruby sales and new data showing superiority fuel BridgeBio’s momentum as it prepares for three FDA decisions, backed by a new $1B financing.

Two years after a landmark rejection, the bid to approve MDMA-assisted therapy for PTSD is back. This is more than a resubmission; it's a test case for a new paradigm in medicine.

AOM Capital's recent $5.1M financing for a drug acquisition showcases the rise of specialty lenders in the high-stakes world of pharmaceutical M&A.

Indian pharma giant Lupin secures FDA approval for a generic heart drug, challenging AstraZeneca and signaling a new era of cost competition in specialty medicine.

ITM’s promising cancer drug ITM-11 hits a delay, not for its science, but for manufacturing. A classic 'prototype to profit' hurdle with big implications.

Bristol Myers Squibb's massive Texas campus isn't just about jobs. It's a high-tech play to reshore drug manufacturing and revolutionize how we make medicine.

Heron Therapeutics withdraws guidance after a patent blow to its top drug, forcing a strategic review. Can strong growth in new acute care products save it?

A new drug, divesiran, shows stunning success in trials, offering hope to those with a rare blood cancer by potentially replacing frequent phlebotomies with a quarterly shot.

Amid its pending sale to Zymeworks, Theravance Biopharma’s Q2 results reveal a lesson in resilience, with strong YUPELRI sales and deep cost cuts.

Health Canada's approval of Fasenra for HES marks a new era for patients. This is the story of how one drug intersects with patient hope and national policy.

Grifols completes its landmark SPARTA trial for a rare lung disease, offering new hope to patients and signaling a major strategic move in the biotech market.

A Korean firm's breakthrough tech bypasses freezing temps for vaccines. This isn't just a business win; it's a blueprint for a more accessible future.